Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042406 · ClinicalTrials.gov registry record · Phase 2
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
A Phase 2 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00042406: Clinical Trial Phase 2 study, sponsored by Genmab.
NCT00042406 is a Phase 2 study that was terminated before completion, run by Genmab. The registered enrollment target is 83 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042406, a Phase 2 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
Interventions
- DRUG Placebo
- DRUG HuMax-CD4
- DRUG Humax-CD4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2002-03-04 |
| Est. Completion | 2003-03-31 |
| Phase | Phase 2 |
Why NCT00042406 stopped before completion
NCT00042406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00042406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00042406 about?
NCT00042406 is a clinical study titled "Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker". The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
What is the current status of trial NCT00042406?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2002-03-04. Estimated completion is 2003-03-31.
What interventions are being tested in trial NCT00042406?
The interventions under investigation include: Placebo (DRUG), HuMax-CD4 (DRUG), Humax-CD4 (DRUG).
Who is sponsoring clinical trial NCT00042406?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00042406's enrollment target sits among peer trials
83 828th of 2000 higher than 1,171 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI